Efficacy Study of Vx001 Vaccine in NSCLC Patients
Read time: 1 mins
Last updated:26th Aug 2013
Patients with stage IV or recurrent stage I-III NSCLC with documented disease control (objective response or stable disease) within 3 weeks after platinum based 1st line chemotherapy; only HLA-A*0201 positive patients with TERT expressing tumors will be included. The objective of the trial is survival rate at 12 months.
|Study start date||2013-08-26|